Folgen
Keine Story von OxThera AB mehr verpassen.

OxThera AB

Filtern
  • 07.09.2018 – 11:47

    Hugo Petit Appointed CFO of OxThera

    Stockholm (ots/PRNewswire) - OxThera AB, a Stockholm-based privately-held rare disease company today announced the appointment of Hugo Petit as its new Chief Financial Officer. Mr Petit previously served as the Chief Financial Officer of MedCap AB. While at MedCap, Hugo led the company's listing on Nasdaq Stockholm. Prior to joining MedCap, Hugo held several roles as Chief Financial Officer in small as well as medium ...

  • 12.06.2018 – 17:59

    OxThera Announces the Appointment of Dr Alain Munoz to its Board of Directors

    Stockholm (ots/PRNewswire) - OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the appointment of Dr Alain Munoz to its board of directors. "It is my pleasure to welcome Alain to the board of Oxthera," said Dr. Georges Gemayel, Chairman of Oxthera. ...

  • 08.11.2017 – 20:03

    OxThera Strengthens Patent Portfolio for Treatment of Hyperoxaluria

    Stockholm (ots/PRNewswire) - OxThera AB announced today that it has recently been granted two new US patents, three new European patents and patents in Canada, China, Hong-Kong, India and Japan. OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families. The newly granted US patents have ...

  • 13.10.2017 – 08:57

    Dr. Bastian Dehmel Appointed CMO of OxThera

    Stockholm (ots/PRNewswire) - OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Dr. Bastian Dehmel as their new Chief Medical Officer. OxThera is developing a novel treatment, Oxabact, for Primary Hyperoxaluria (PH), a severe and often fatal disease in children, and where there are currently no available therapies. The company is poised to initiate a pivotal Phase III ...